Know Cancer

or
forgot password

A Pilot Study- Prevention of Capecitabine Induced Hand and Foot Syndrome


N/A
18 Years
N/A
Not Enrolling
Both
Cancer

Thank you

Trial Information

A Pilot Study- Prevention of Capecitabine Induced Hand and Foot Syndrome


Capecitabine is a common anti cancer drug. One of the most common side effects is a syndrome
called hand and foot syndrome which comprises of hands and feet redness, swelling, dryness
and painful sores. Quite often the drug dose is reduced to suboptimal level due to this side
effect. There is no way to prevent or an effective way to treat this side effect. Our aim is
to investigate whether wearing socks which contain copper fibers may prevent or alleviate
the patient symptoms.

The patients will use socks containing copper-oxide impregnated fibers which are sold in the
Pharma stores without physician's prescription.(EPA numbers 8454-2, 8454-3 from April 30
2009).

Drug Toxicity and skin reaction will be documented.


Inclusion Criteria:



- Clinical diagnosis of stage IV cancer - treated with Capecitabine

Exclusion Criteria:

- Any patient who can not sign an informed consent

- Pregnant women

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention

Outcome Measure:

skin feet toxicity

Outcome Description:

within the first year from starting Capecitabine use

Outcome Time Frame:

1 year

Safety Issue:

No

Principal Investigator

Rinat Yerushalmi, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Rabin Medical Center, Affiliated to Tel-Aviv University, Tel-Aviv, Israel

Authority:

Israel: Ministry of Health

Study ID:

Socks

NCT ID:

NCT01291628

Start Date:

January 2012

Completion Date:

January 2014

Related Keywords:

  • Cancer
  • Capecitabine
  • Hand and foot syndrome
  • Socks
  • Copper
  • Toxicity

Name

Location